Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer

Internal Medicine

Volumn 40, Issue 7, 2001, Pages 603-606

  Matsui, Kaoru ^a   Masuda, Noriyuki ^a   Yana, Takashi ^a   Takada, Yoshiaki ^a   Kobayashi, Masashi ^a   Nitta, Takashi ^a   Hirashima, Tomonori ^a   Fukuoka, Masahiro ^b  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aea under the concentration curve; Combination chemotherapy; Dose escalation; Lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0034866074     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.603     Document Type: Article

References (24)

1. Shepherd FA, Amdemichael E, Evans WK, et al. Treatment of small-cell lung cancer in the elderly. J Am Geriatr Soc 42: 64-70, 1994.
2. Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 14: 821-828, 1996.
3. Friedman SA, Raizner AE, Rosen H, Solomon NA, Sy W. Functional Defects in the Aging Kidney. Ann Intern Med 76: 41-45, 1972.
4. Dajczman E, Fu LY, Small D, Wolkove N, Kreisman H. Treatment of small cell lung carcinoma in the elderly. Cancer 77: 2032-2038, 1996.
5. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 5: 1574-1578, 1987.
6. Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin-Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18: 149-155, 1995.
7. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 573-580, 1995.
8. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, Switzerland, World Health Organization, 1979.
9. Johnson DH. Small Cell Lung Cancer in the Elderly Patient. Semin Oncol 24: 484-491, 1997.
10. Coebergh JW. Significant trends in cancer in the elderly. Eur J Cancer 32A: 569-571, 1996.
11. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44: 631-633, 1989.
12. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 17: 49-53, 1990.
13. Miller AA, Herndon JE, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13: 1871-1879, 1995.
14. Smith IE, Evans BD, Gore ME, et al. Carboplatin (Paraplatin; JM8) and Etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5: 185-189, 1987.
15. Carney DN. Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Lung Cancer 12 (Suppl 3): S77-83, 1995.
16. Burn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 16: 27-33, 1989.
17. Matsui K, Masuda N, Fukuoka M, et al. Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 77: 1961-1965, 1998.
18. Balducci L, Parker M, Sexton W, Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 16 : 76-84, 1989.
19. Phister JE, Jue SG, Cusack BJ. Problems in the use of anticancer drugs in the elderly. Drugs 37: 551-565, 1989.
20. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
21. Murray N, Payne DG, Coldman AJ. Multimodality therapy for limited stage small cell lung cancer: Combining chemotherapy and thoracic irradiation, in: Lung Cancer-Principles and Practice. Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Eds. Lippincott-Raven, New York, 1996: 875-892.
22. Johnson DH, Bass D, Einhorn LH, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 11: 1223-1229, 1993.
23. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 15: 893-900, 1997.
24. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618-1624, 1992.